May 10, 2019 7:20pm

“The Strange Case of Dr. Jekyll and Mr. Hyde might make for a great read, but it’s far less fun when the markets act like it’s their blueprint. Stocks have lately been alternating between the horrific and the benign”.

Pre-open indications of post earnings releases: 4 HITs and 4 MISS (3 by pennies)

Q1 results: Brainstorm Cell Therapy (BCLI -$0.02)

The truth is unforgiving re Biostage (BSTG), but reality is what it is – a disaster oriented company with a very short “runway”!  

Lucky to be reading a freebee instead of spending time looking for what’s happening on a messy Friday, if you were a subscriber …

 

Markets and indexes:

  • The Dow closed up +114.01 points or +0.44% to 25,942.37
  • The S&P closed up +10.68 points or +0.37% at 2,881.40
  • The NASDAQ was up +6.35 points or +0.08% to 7,916.94

`

Henry’omics:

Markets staged a massive reversal on Friday after President Trump said conversations with China over trade will continue and his relationship with President Xi Jinping remains strong.

While sector equities fell again on Friday, resuming a deep sell-off on Thursday.

Even with Friday's rebound, the S&P 500 and the NASDAQ logged their biggest weekly percentage losses of the year. For the week, the Dow fell 2.12%, the S&P 500 declined 2.17% and the NASDAQ shed 3.03%.

Pre-open post, “TGIF, this week ends and still no tariff deal as indexes fall.”

Despite Friday's gain, the S&P 500 still suffered its worst week of the year, losing nearly 2.2%.

  • ReNeuron (RENE.L) was down again (-$6.00 after Thursday’s -$17.00, Wednesday’s -$14.50 and Tuesday’s -$7.50) along with Sage Therapeutics (SAGE) -$4.22
  • While UniQure (QURE) broke to the upside +$3.82 followed by Ions Pharmaceuticals (IONS) +$1.92.

It's (the week) is over ... next week is on the radar ... review the week's stats!!

 

From this morning’s “bully pulpit” post:

Biostage (BSTG) closed up +$0.05 but, who is trading or playing these “trades” – I smell something – maybe the SEC should be reviewing!!

On 5/14’s earnings’ release – let’s talk cash position, runway and status of the always missed IND filing – continually to the future. They have yet to file one (1) after all their “talk”, porcine surgeries and how many millions spent ($70 M +).

A history of unfulfilled expectations by this management team’s mistruths and failure to communicate – yet again, so let’s be ready for 5/14’s next story line!

Read, from the a.m. post: RegMed Investors’ (RMi) pre-open: TGIF, the week ends and still no tariff deal as indexes fall … https://www.regmedinvestors.com/articles/10842

 

Friday’s advance/decline line scenario of 45 covered companies:  

  • The open was negative with the A/DL at 15/27, 1 flat and 2 acquired (AST & OSIR);
  • The mid-day was negative with an A/DL of 15/28 and 0 flat and 2 acquired;
  • The close was negative with an A/DL of 21/22 and 0 flat and 2 acquired;

 

Pre-open indications: 4 HITs and 4 MISS

  • Biostage (BSTG) closed up +$0.05 – miss;
  • Ionis Pharmaceuticals (IONS) closed up +$1.92 – hit;
  • Caladrius Biosciences (CLBS) closed down -$0.09 – hit;
  • Verastem Oncology (VSTM) closed down -$0.53 – hit;
  • Intrexon (XON) closed up +$0.04 – miss;
  • BioLife Solutions (BLFS) closed down -$0.19 – miss;
  • BioTime (NYSEMKT: BTX) closed up +$0.03 – hit;
  • Stemline Therapeutics (STML) closed up +$0.02 – miss;

 

Cell and gene therapy company’s worst-performers were:

  • Friday: RENE.L (-$6.00), SAGE (-$4.22), BMRN (-$0.95), ALNY (-$0.68) and SLDB (-$0.54);
  • Thursday: RENE.L (-$17.00), SGMO (-$1.67), QURE (-$1.47), IONS (-$1.29) and RARE (-$1.01);
  • Wednesday: RENE.L (-$14.50), BLUE (-$4.53), RGNX (-$4.25), AXGN (-$1.42) and ADRO (-$0.93);
  • Tuesday: BLUE (-$10.29), RENE.L (-$7.50), IONS (-$5.12), RARE (-$4.68) and SAGE (-$3.53);
  • Monday: ALNY (-$3.21), RARE (-$0.74), IONS (-$0.72), BMRN (-$0.63) and AXGN (-$0.50);

Sector equities posting gains were:

  • Friday: QURE (+$3.82), IONS (+$1.92), RARE (+$1.66), FATE (+$0.88) and GBT (+$0.70);
  • Thursday: ALNY (+$1.99), BLUE (+$1.030, AXGN (+$0.90), BMRN (+$0.66) and BOLD (+$0.52);
  • Wednesday: SAGE (+$2.86), GBT (+$2.46), IONS (+$1.03), VYGR (+$0.97) and RARE (+$0.89);
  • Tuesday: ADRO (+$0.15), ADVM (+$0.08), BCLI (+$0.05), ONCE (+$0.05) and KOOL (+$0.013);
  • Monday: RENE.L (+$20.00), BLUE (+$3.99), SAGE (+$3.69), NTLA (+$1.66) and VYGR (+$1.53);

 

The week’s percentage (%) indicators: 

  • Friday’s range of the 21 upside was +0.11% (CLLS) to +6.67% (QURE) while the 22 downside ranged from -0.01% (ONCE) to -28.04% (VSTM);
  • Thursday’s range of the 20 upside was +0.24% (FATE) to +7.83% (BSTG) while the 23 downside ranged from -0.06% (VCEL) to -14.77% (SGMO);
  • Wednesday’s range of the 24 upside was +0.12% (ONCE) to +4.74% (XON) while the 18 downside ranged from -0.09% (SGMO) to -21.09% (ADRO);
  • Tuesday’s range of the 6 upside was +0.05% (ONCE) to +4.92% (KOOL) while the 36 downside ranged from -0.61% (SLDB) to -8.65% (XON);
  • Monday’s range of the 32 upside was +0.47% (AGTC) to +17.65% (MDXG) while the 8 downside ranged from -0.75% (BMRN) to -4.15% (ALNY)

Upside volume stats:  review the numbers, there is a message …

  • Friday: 4 out of the 21 upside had higher than the 3 month average volume;
  • Thursday: 4 out of the 20 upside had higher than the 3 month average volume;
  • Wednesday: 4 out of the 24 upside had higher than the 3 month average volume;
  • Tuesday: 2 out of the 6 upside had higher than the 3 month average volume;
  • Monday: 7 out of the 32 upside had higher than the 3 month average volume;

Downside volume stats: here is where the session landing is expressed …

  • Friday: 6 out of the 22 downside had higher than the 3 month average volume;
  • Thursday: 5 out of the 23 downside had higher than the 3 month average volume;
  • Wednesday: 8 out of the 18 downside had higher than the 3 month average volume;
  • Tuesday: 10 out of the 36 downside had higher than the 3 month average volume;
  • Monday: 2 out of the 8 downside had higher than the 3 month average volume;

0 flat with 2 acquired (AST & OSIR)

 

Q1/19 results:

BrainStorm Cell Therapeutics (BCLI)

Net loss was $5 M, or -$0.24 per share, as compared to a net loss of $2.3 M, or -$0.12 per share for Q1/18.

Cash, cash equivalents, and short-term bank deposits were $6.23 M compared with $7.8 M at FY18’s end.  Cash including short-term bank deposits) and cash commitments including the remaining commitments of $3 M from the CIRM grant and approximately $1 M under the IIA 2018 grant) amounted to approximately $10.23 M.

Runway: 2019

 

The iShares NASDAQ Biotechnology (IBB) indicator:

  • Friday closed down -0.32%
  • Thursday closed down -0.24%
  • Wednesday closed down -0.04%
  • Tuesday closed down -2.94%
  • Monday closed up +0.85%
  • Last Friday closed up +1.82%

 

May’s sessions:

Friday closed NEGATIVE with 22 decliners, 21 advancers, 0 flat and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 23 decliners, 20 advancers, 0 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 18 decliners, 24 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 36 decliners, 6 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 8 decliners, 32 advancers, 3 flat and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 4 decliners, 37 advancers, 2 flat and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 23 decliners, 17 advancers, 3 flat and 2 acquired (AST & OSIR);

Wednesday (5/1) closed NEGATIVE with 30 decliners, 12 advancers, 1 flat and 2 acquired (AST & OSIR);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.